MedTrace Logo

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

NCT01655888 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2012-08-02

No results posted yet for this study

Summary

RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of tremelimumab in malignant mesothelioma (MM) patients.

PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks until confirmed disease progression.

Conditions

  • Malignant Mesothelioma

Interventions

DRUG

Tremelimumab

Tremelimumab is administered as endovenous infusion

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • Azienda Ospedaliera Universitaria Senese

    lead OTHER

Principal Investigators

  • Michele Maio, MD · Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Italy

  • Luana Calabrò, MD · Medical Oncology and Immunotherapy, University Hospital of Siena, Italy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-01-31
Completion
2015-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01655888 on ClinicalTrials.gov